- Market Capitalization, $K 1,123,951
- Shares Outstanding, K 147,694
- Annual Sales, $ 69,720 K
- Annual Income, $ -562,540 K
- 60-Month Beta 1.20
- Price/Sales 15.66
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
-3.17 (-29.41%)since 04/20/22
| || |
-0.47 (-5.82%)since 02/18/22
| || |
-11.46 (-60.10%)since 05/20/21
- PTR-01 was well-tolerated over a four-month treatment period in RDEB patients - Treatment with PTR-01 led to rapid, consistent, and durable wound...
Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.
BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.
Because of this stock market crash, some wonderful stocks are super cheap in 2022. Here's a mini-portfolio of innovative companies trading under $10 a share right now.
-Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV) it obtained in February 2021 for $110 million ...
- BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to $815 million in additional milestone payments...
PALO ALTO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -5.31% and 80.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
–Completed sale to Sentynl Therapeutics of BridgeBio’s NULIBRY™ (Fosdenopterin) for Injection–Updated strategic collaboration with Helsinn Group to...
Personalis (PSNL) delivered earnings and revenue surprises of -10.53% and 2.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
|Bridgebio Pharma Inc|
|S&P Biotech SPDR|
|Principal Healthcare Innovators Index|
|Bioshares Biotech Clinical Trial|
|U.S. Liquidity Factor Vanguard ETF|
|Invesco Nasdaq Biotechnology ETF|